Peter Svalander
Corporate Officer/Principal presso University of Gothenburg
Posizioni attive di Peter Svalander
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of Gothenburg | Corporate Officer/Principal | 02/06/2010 | - |
Storia della carriera di Peter Svalander
Precedenti posizioni note di Peter Svalander
Società | Posizione | Inizio | Fine |
---|---|---|---|
Swedish Biotechnology AB | Presidente | - | - |
Avaris AB
Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Direttore/Membro del Consiglio | - | - |
Statistiche
Distribuzione geografica
Svezia | 4 |
Posizioni
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
President | 1 |
Settori
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Swedish Biotechnology AB | |
Avaris AB
Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
- Borsa valori
- Insiders
- Peter Svalander
- Esperienza